The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens
This study has been completed.
Sponsor:
University of California, Davis
Information provided by (Responsible Party):
University of California, Davis
ClinicalTrials.gov Identifier:
NCT01626300
First received: June 20, 2012
Last updated: June 21, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the daily use of a certain amount and type of milk component for 2 months provides a significant stimulation to the immune system and specifically increases the chances of being protected against pneumonia after the vaccination.
| Condition |
|---|
|
To Evaluate the Effects of Milk Components (Whey and/or Inulin) on the Response to Pneumococcal Vaccines in the Elderly. |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
| Official Title: | The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens: A Randomized Placebo-controlled Clinical Trial |
Resource links provided by NLM:
Further study details as provided by University of California, Davis:
Eligibility| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
Healthy subjects > 60 years of age.
Criteria
Inclusion Criteria:
- Age and a willingness to participate
Exclusion Criteria:
• Smoking history within 10 years
- Underlying neoplasia or immunological disease
- Use of oral cortisone or other immunosuppressive agents
- Current consumption of milk and milk products greater than 1 unit of milk, 1 yogurt, or 1 serving of fresh cheese a day.
- Food faddists or those taking a non-traditional diet
- Current consumption of dietary supplements
- People with a known history of milk allergy
- People with chronic renal failure
- People with chronic inflammatory diseases taking daily doses of NSAIDs for longer than 4 weeks at the time of enrollment.
- Previous administration of the pneumomax vaccine
- Reduced physical activity (i.e. NYHA classes III-IV)
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | University of California, Davis |
| ClinicalTrials.gov Identifier: | NCT01626300 History of Changes |
| Other Study ID Numbers: | 200513884-2 |
| Study First Received: | June 20, 2012 |
| Last Updated: | June 21, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |
ClinicalTrials.gov processed this record on May 23, 2013